Know About EKRA Law in 2023 | Oberheiden P.C.
WSJ logo
Forbes logo
Fox News logo
CNN logo
Bloomberg logo
Los Angeles Times logo
Washington Post logo
The Epoch Times logo
Telemundo logo
New York Times
NY Post logo
NBC logo
Daily Beast logo
USA Today logo
Miami Herald logo
CNBC logo
Dallas News logo
Quick Practice Area Locator

5 Things You Must Know About EKRA Law in 2023


The Eliminating Kickbacks in Recovery Act (“EKRA”) was passed by Congress on October 24, 2018 as a part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT) Act.

It targets patient brokers who seek to profit from illegal patient referrals by prohibiting laboratories, clinics, recovery centers, and other clinical treatment facilities from accepting or paying kickbacks for such referrals.

Put our highly experienced team on your side

Dr. Nick Oberheiden
Dr. Nick Oberheiden



Lynette S. Byrd
Lynette S. Byrd

Former DOJ Trial Attorney


Brian J. Kuester
Brian J. Kuester

Former U.S. Attorney

Amanda Marshall
Amanda Marshall

Former U.S. Attorney

Local Counsel

Joe Brown
Joe Brown

Former U.S. Attorney

Local Counsel

John W. Sellers
John W. Sellers

Former Senior DOJ Trial Attorney

Linda Julin McNamara
Linda Julin McNamara

Federal Appeals Attorney

Aaron L. Wiley
Aaron L. Wiley

Former DOJ attorney

Local Counsel

Roger Bach
Roger Bach

Former Special Agent (DOJ)

Chris Quick
Chris J. Quick

Former Special Agent (FBI & IRS-CI)

Michael S. Koslow
Michael S. Koslow

Former Supervisory Special Agent (DOD-OIG)

Ray Yuen
Ray Yuen

Former Supervisory Special Agent (FBI)

In this blog post, we explain five things you must know about EKRA law to be prepared for 2023.

1. The Eliminating Kickbacks in Recovery Act (“EKRA”) represents another aggressive step by the federal government to counter the national opioid crisis in the United States.

The Eliminating Kickbacks in Recovery Act (“EKRA”), 18 U.S.C. § 220, makes it a federal crime for anyone, with respect to services covered by a health care benefit program, to knowingly and willfully:

  • solicit or receive any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind, in return for referring a patient or patronage to a recovery home, clinical treatment facility, or laboratory; or
  • pay or offer any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind-
    • to induce a referral of an individual to a recovery home, clinical treatment facility, or laboratory; or
    • in exchange for an individual using the services of that recovery home, clinical treatment facility, or laboratory.

Violations of this provision subjects the individual to a fine of not more than $200,000, an imprisonment term of not more than 10 years, or both, for each occurrence.

Additional violations that may be imposed include sanctions, licensure revocations, or the exclusion from participating in governmental healthcare programs.

The agencies charged with the enforcement and prosecution of EKRA are the Department of Health and Human Services and the DOJ.

2. Individuals have already pled guilty to EKRA violations as a result of DOJ investigations, and this trend is likely to continue in 2023.

The DOJ has already begun prosecuting individuals under EKRA. For instance, in early 2020, an office manager of a substance abuse treatment clinic pleaded guilty to EKRA law violations through her solicitation of kickbacks from a toxicology lab in exchange for referrals.

Recently in September 2020, two men pled guilty for conspiracy to commit health care fraud and conspiracy to violate EKRA. Their conduct entailed an elaborate multi-state patient brokering scheme by which their marketing company recruited patient referrals in exchange for kickbacks covered by health care program reimbursements.

The DOJ plans to continue its aggressive approach in 2023, especially in the midst of the rapid increase in pandemic-related fraud cases.

3. EKRA is broader than the federal Anti-Kickback Statute and other federal statutes.

EKRA has received criticism for its potential to criminalize conduct that was permissible under the federal Anti-Kickback Statute and other federal statutes. Broadly, the Anti-Kickback Statute prohibits knowing and willful payments to induce patient referrals or generate business involving any service payable to governmental health care programs. In other words, the Anti-Kickback Statute is limited to federal and state healthcare programs.

Under EKRA, health care benefit programs include not only state and federal health care programs (e.g., Medicare and Medicaid) but also private health insurance plans. EKRA’s reach is therefore more extensive than the Anti-Kickback Statute. It potentially applies any time an entity provides medical services and regardless of whether such services are covered by government insurance plans (federal or state), private health insurance plans, or even in cases where the patients themselves pay.

Additionally, EKRA contains less exemptions than the Anti-kickback Statute. While the Anti-Kickback Statute contains statutory and regulatory safe habors, the EKRA statute has less statutory safe harbors and no regulatory safe harbors. Therefore, conduct that was once exempt from the Anti-Kickback Statute is now prohibited by EKRA. Examples of EKRA exemptions are payments to bona fide employees, remuneration paid pursuant to “alternative payment models”, remuneration paid to Federally Qualified Health Centers, and others.

Because of the lack of federal guidance, individuals and entities are left in an uncertain state as to which conduct is prohibited and how to reconcile the differences between EKRA and other federal and state legislation prohibiting kickbacks.

4. EKRA significantly alters the nature of the relationship between laboratories and their marketing and sales personnel.

Under federal law, a laboratory is defined as the “facility for the . . . examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings.” EKRA substantially changes the relationship between laboratories, clinics, recovery centers, or other clinical treatment facilities and their marketing and sales personnel. As mentioned, the text of EKRA appears to prohibit certain commonly accepted business practices such as paying of sales commissions to marketing personnel or giving free equipment to physician clients. This conduct was a traditionally accepted practice and was not prohibited under the Anti-Kickback Statute, though it is now prohibited under EKRA.

Also, EKRA applies regardless of the entity’s medical business operations and regardless of payor. Even though EKRA was intended to combat the growing opioid epidemic, the text of the statute is broader than the purpose.

As a result, a clinical laboratory may now be forced to revise and amend their marketing, sales, and patient broker arrangements in order to be compliant with EKRA laws.

5. Violations of EKRA law may also violate other federal statutes.

EKRA prohibits anyone from knowingly and willfully soliciting or receiving remuneration or paying or offering remuneration—kickbacks—with respect to the services of a health care benefit program. Violating this provision can subject an individual or entity to liability under other federal statutes such as legislation that prohibits making false statements as well as the False Claims Act.

An individual or entity violates the False Claims Act each and every time they submit a claim that they know is false with respect to a federal government program.

Because of this, it is incumbent upon individuals and entities in the healthcare industry to re-evaluate the terms of their sales and marketing arrangements to ensure that they are in compliance with EKRA.

Hiring an EKRA lawyer who fully understands the EKRA compliance and implications of EKRA laws would help safeguard your business operations, professional license, and reputation. Reach out to the team at Oberheiden, P.C. today.

Speak with an EKRA Attorney Today

For more information about taking legal action to protect your business or practice, we encourage you to schedule an initial consultation at Oberheiden, P.C.. Our attorneys represent clients in multiple states across the nation in civil litigation, qui tam investigation, healthcare fraud defense, and other legal matters.

To schedule an appointment, please call our offices at 888-680-1745 or send us your information online and our EKRA attorney will be in touch as soon as possible.

Last Updated:

Contact Us Today

I accept the Terms and Conditions.(Required)
WordPress Lightbox